BiPar Sciences, Inc.

1000 Marina Blvd., Suite 550
94005 Brisbane
USA

Company Portrait

BiPar Sciences is a privately held biopharmaceutical company pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients, with headquarters in Brisbane, California. In addition to BSI-201, the company also has two additional compounds in pre-clinical development, BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer and BSI-302, a novel anti-tubulin agent, that targets cancer cells based on the role of thyroid hormones in cell proliferation and death.

Industrial Sectors

Pharma

Watchlist

This is where you can add this company to your personal favourites

On my watchlist

More about BiPar Sciences

News

Sanofi-aventis: BSI-201 enters phase III in metastatic triple negative breast cancer

Sanofi-aventis and its wholly owned subsidiary, BiPar Sciences, announced the initiation of the pivotal Phase III trial for BSI-201 in combination with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC), defined by tumors lacking expression of estrogen, progester ... more

Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company

Sanofi-aventis announced that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc., a privately held US biopharmaceutical company, developing novel tumorselective approaches for the treatment of different types of cancers. BiPar is a company in the emerging field o ... more
Companies

BiPar Sciences, Inc.

BiPar Sciences is a privately held biopharmaceutical company pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients, with headquarters in Brisbane, California. In addition to BSI-201, the company also has two additional compounds in pre-clinical ... more

Top Companies

other

Topics A-Z

All topics